Enteric Coated Mycophenolate Sodium (EC-MPS)

DRUG5 trials

Sponsors

Novartis Pharmaceuticals, Gaetano Ciancio

Conditions

Chronic Renal FailureHeart TransplantationKidney TransplantationRenal FunctionRenal TransplantationTransplant; Failure, Kidney

Phase 3

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

CompletedNCT01680861

Gaetano CiancioTransplant; Failure, Kidney

Start: 2012-11-30End: 2014-12-31Updated: 2016-12-15

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

CompletedNCT01843348

Novartis PharmaceuticalsKidney Transplantation, Renal Transplantation

Start: 2012-12-27End: 2016-03-23Updated: 2017-05-01

Phase 4

Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

CompletedNCT00634920

Novartis PharmaceuticalsRenal Function

Start: 2008-03-31End: 2013-05-31Updated: 2014-08-13

A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

CompletedNCT00862979

Novartis PharmaceuticalsHeart Transplantation

Start: 2009-02-24End: 2017-03-06Updated: 2018-08-07

Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients

CompletedNCT00965094

Novartis PharmaceuticalsChronic Renal Failure

Start: 2009-12-31End: 2013-06-30Updated: 2014-08-15

Related Papers

Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy

Frontiers in Transplantation2023-11-214 citations

COUNTRY-DEPENDENT OUTCOME DIFFERENCES AFTER KIDNEY TRANSPLANTATION IN FRANCE VS. GERMANY – AN ADDITIONAL ANALYSIS OF THE ATHENA STUDY

Transplantation2020-08-28

ATHENA VS HEPHAISTOS - ARE DISCONTINUATION RATES IN MULTICENTER STUDIES DRIVEN BY FACTS OR ATTITUDES?

Transplantation2020-08-28

MANDELA Study Results at 18 Months after Heart Transplantation

Transplantation2018-07-012 citations

Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.

2016-02-1711 citations